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Open Forum Infectious Diseases®
Invasive Obstetric Procedures and Cesarean Sections in 
Women With Known Herpes Simplex Virus Status During 
Pregnancy
Helen C. Stankiewicz Karita,1 Nicholas J. Moss,6 Ellen Laschansky,2 Linda Drolette,3 Amalia S. Magaret,3,4,5 Stacey Selke,1,3,7 
Carolyn Gardella,2 and Anna Wald1,3,5,7
Departments of 1Medicine, 2Obstetrics and Gynecology, 3Laboratory Medicine, 4Biostatistics, and 5Epidemiology, University of Washington, Seattle; 6Division of Communicable Disease Control and 
Prevention, Alameda County Public Health Department, Oakland, California; and 7Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
Background. Neonatal herpes is a potentially devastating infection that results from acquisition of herpes simplex virus (HSV) 
type 1 or 2 from the maternal genital tract at the time of vaginal delivery. Current guidelines recommend (1) cesarean delivery if 
maternal genital HSV lesions are present at the time of labor and (2) antiviral suppressive therapy for women with known genital 
herpes to decrease HSV shedding from the genital tract at the time of vaginal delivery. However, most neonatal infections occur 
in infants born to women without a history of genital HSV, making current prevention efforts ineffective for this group. Although 
routine serologic HSV testing of women during pregnancy could identify women at higher risk of intrapartum viral shedding, it is 
uncertain how this knowledge might impact intrapartum management, and a potential concern is a higher rate of cesarean sections 
among women known to be HSV-2 seropositive.
Methods. To assess the effects of prenatal HSV-2 antibody testing, history of genital herpes, and use of suppressive antiviral 
medication on the intrapartum management of women, we investigated the frequency of invasive obstetric procedures and cesarean 
deliveries. We conducted a retrospective cohort study of pregnant women delivering at the University of Washington Medical center 
in Seattle, Washington. We defined the exposure of interest as HSV-2 antibody positivity or known history of genital herpes noted in 
prenatal records. The primary outcome was intrapartum procedures including fetal scalp electrode, artificial rupture of membranes, 
intrauterine pressure catheter, or operative vaginal delivery (vacuum or forceps). The secondary outcome was incidence of cesarean 
birth. Univariate and multivariable logistic regressions were performed.
Results. From a total of 449 women included in the analysis, 97 (21.6%) were HSV-2 seropositive or had a history of genital 
herpes (HSV-2/GH). Herpes simplex virus-2/GH women not using suppressive antiviral therapy were less likely to undergo intra-
partum procedures than women without HSV-2/GH (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.25–0.95; P = .036), but 
this relationship was attenuated after adjustment for potential confounders (adjusted OR, 0.69; 95% CI, 0.34–1.41; P = .31). There 
was no difference in intrapartum procedures for women on suppressive therapy versus women without HSV-2/GH (OR, 1.17; 95% 
CI, 0.66–2.07; P = .60). Similar proportions of cesarean sections were performed within each group of women: 25% without history 
of HSV-2/GH, 30% on suppressive treatment, and 28.1% without suppressive treatment (global, P = .73).
Conclusions. In this single-site study, provider awareness of genital herpes infection either by HSV serotesting or history was 
associated with fewer invasive obstetric procedures shown to be associated with neonatal herpes, but it was not associated with an 
increased rate of cesarean birth.
Keywords. cesarean section; genital herpes; herpes simplex virus-2; pregnancy; suppressive therapy.
 
Neonatal herpes is a rare but potentially devastating infection of 
infants that usually results from infection with herpes simplex 
virus (HSV) type 1 or 2 in the maternal genital tract at the time 
of vaginal birth. The incidence of neonatal herpes ranges from 
8 to 60 cases per 100 000 live births in the United States [1–6]. 
To date, prevention efforts have focused on avoiding neona-
tal exposure to HSV in genital secretions of infected pregnant 
women by performing cesarean delivery in women with genital 
lesions at the time of labor. However, most cases of neonatal 
herpes occur among infants born to women with asymptom-
atic genital HSV, especially those who become infected late 
in pregnancy [1, 7–9]. Thus, the strategy of cesarean delivery 
for women with lesions in labor fails to address the majority 
of cases [1]. Intrapartum procedures, such as operative vaginal 
delivery or use of fetal scalp electrodes, can disrupt the fetal 
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skin and increase the risk of HSV exposure in the genital tract, 
thus increasing the risk of neonatal herpes infection [1, 10]. 
Membrane rupture also contributes to risk [11]. Avoiding intra-
partum procedures in women with antibodies to HSV-2 could 
decrease risk of neonatal herpes.
Herpes simplex virus antibody testing identifies women with 
HSV infection, and maternal HSV antibody testing may be 
helpful in identifying neonates at risk of intrapartum HSV ex-
posure. However, routine prenatal serology testing for HSV is 
not currently recommended due to lack of cost-effective screen-
ing strategies and lack of evidence that antiviral treatment in 
asymptomatic HSV-2-seropositive women will decrease neo-
natal herpes infection [12]. Maternal HSV antibody status, in 
addition to clinical history, could inform provider decision 
making at delivery and decrease the use of intrapartum proce-
dures associated with increased neonatal herpes risk in asymp-
tomatic women with genital HSV infection. However, a concern 
about such a screening strategy is that it may increase the rate of 
cesarean deliveries among HSV-2-seropositive women [13, 14].
Herpes simplex virus antibody testing has been done routinely 
as part of prenatal care at the University of Washington Medical 
Center (UWMC). To assess the effect of provider knowledge 
regarding HSV status either by serology or history on intrapartum 
management, we compared the frequency of invasive intrapartum 
procedures and of cesarean births among pregnant women with 
either HSV-2 antibody or a clinical history of herpes to those in 
women with no evidence of genital HSV infection.
METHODS
Subjects and Setting
We conducted a retrospective cohort study of 750 consecutive 
deliveries performed in 2006 at the UWMC, a quaternary care 
referral center serving the Pacific Northwest that performs ap-
proximately 2000 deliveries per year. We reviewed charts using 
a standardized data collection form and abstracted data on HSV 
antibody result, clinical history of genital herpes, demographics, 
use of intrapartum procedures, final method of delivery, and 
underlying conditions and complications of pregnancy or de-
livery. A  subset of charts was audited to confirm accuracy of 
data collection. We included women with any HSV antibody 
result or genital herpes history. Women with active genital 
lesions suspicious for HSV during labor were excluded. Women 
with nonvertex fetal presentation were excluded because this 
was assumed, a priori, to be very strongly associated with ce-
sarean delivery. Women undergoing scheduled cesarean births 
were also excluded from the analysis, because they are not at 
risk for intrapartum procedures, and the impact of genital HSV 
infection status on provider decisions during labor cannot be 
evaluated.
We extracted demographic characteristics of the women and 
other aspects of the medical and obstetric history. History of gen-
ital herpes was ascertained from the clinical history interview 
obtained during prenatal care, and HSV Western blot ana-
lysis was obtained with other prenatal serologies. Other varia-
bles included parity, prematurity, gestational number, failure to 
progress in labor, group B streptococcus culture, induction of 
labor, placental abruption, fetal distress, high-risk pregnancy, 
and other sexually transmitted diseases (STDs). Prematurity 
was defined as delivery before 37 weeks. High-risk pregnancy 
was defined by the presence of any one of several maternal and 
fetal factors. Maternal factors included asthma, diabetes (includ-
ing gestational), hypertension (including pregnancy-induced), 
pre-eclampsia, renal disease, and cardiac disease. Fetal factors 
included oligohydraminios, intrauterine growth restriction, and 
congenital anomalies. Specific STDs assessed included any his-
tory of syphilis, gonorrhea, chlamydia, trichomoniasis, or human 
papilloma virus diagnosis during pregnancy. The University of 
Washington Institutional Review Board approved the study.
Exposures and Outcomes
We defined the exposure of interest as HSV-2 antibody posi-
tivity or known history of genital herpes (HSV-2/GH) noted 
in the prenatal and delivery records. Herpes simplex virus 
serology was determined using the University of Washington 
Western Blot [15]. We further categorized the exposure based 
on use of suppressive antiviral therapy (acyclovir or valacyclo-
vir) for HSV at the end of pregnancy, because we assumed that 
this could modify any effect of HSV-2/GH status on provider 
behavior and thus on the outcomes of interest. Because orola-
bial infection with HSV-1 is common in the general population, 
we grouped women with only HSV-1 antibody among those 
without any HSV antibody. The primary outcome, intrapartum 
procedures use, was a composite of the following: use of fetal 
scalp electrode, artificial rupture of membranes, intrauterine 
pressure catheter, or vaginal operative (vacuum or forceps) de-
livery. The secondary outcome was cesarean delivery.
Statistical Analysis
We used the χ2 test to compare proportions and the t test to 
compare means. We calculated odds ratios (ORs) and 95% con-
fidence intervals (CIs) using logistic regression and performed 
univariate analyses of the associations between HSV-2/GH with 
and without suppressive therapy and the primary and second-
ary outcomes. We also explored associations between other 
covariates and each outcome that may confound the association 
of HSV-2/GH and the outcomes. Two-sided P values ≤.05 were 
considered statistically significant. For each outcome, we con-
structed an initial multivariable logistic regression model incor-
porating the exposure of interest, HSV-2/GH, and covariates 
that showed possible associations (P  ≤  .1) with that outcome 
in univariate analysis. The final multivariable models were pre-
pared by backwards elimination from each model of covariates 
lacking a strong association with the outcome (P  >  .05). The 
statistical analysis was carried out using Stata versions 9 and 10 
(StataCorp, College Station, TX).
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Study Power
We assumed that approximately 80% of reviewed charts would have 
available data on the exposure of interest, because some participants 
may not have undergone HSV antibody testing. From preliminary 
data, we also estimated a 14% overall prevalence of the exposure, 
HSV-2/GH, in the study population. Although the risk of under-
going several of the intrapartum procedures is less than 10%, on an 
individual basis, in a given delivery, the risk of a composite outcome 
of undergoing any intrapartum procedure is approximately 40% 
at our center. For an outcome with a 40% probability, we had 80% 
power to detect ORs less than 0.47 or greater than 1.96.
RESULTS
Of the 750 charts reviewed, 606 women had known HSV-2/GH 
status. Of the 144 women missing such HSV-2/GH information, 
only 39.7% had received prenatal care at UWMC, with many 
presenting late in pregnancy or during labor, whereas 91.7% 
of women with known HSV-2/GH had received prenatal care 
at UWMC. After excluding women with active genital lesions 
(n  =  2), women with nonvertex fetal presentations (n  =  55), 
and women undergoing scheduled cesarean birth (n  =  100), 
449 women were included in the analysis (Figure 1A). Among 
women who underwent scheduled cesarean births, the indication 
was prior cesarean delivery in 76.3%; indications in the remain-
ing 23.7% were largely a mix of fetal anomalies, macrosomia, 
and maternal anatomic abnormalities. Herpes simplex virus was 
listed as a secondary indication for scheduled cesarean delivery 
in 2 of these women: one who had a primary indication of history 
of fetal shoulder dystocia in a prior delivery and another who 
underwent a planned repeat cesarean delivery. Because there 
was a primary indication for scheduled cesarean birth unrelated 
to HSV in both of these cases, it was assumed that both women 
would have had scheduled cesarean delivery regardless of HSV 
status and the exclusions were judged to be valid.
Of the 449 women included in the analysis, the mean age was 
30.2 years (Table 1). Ninety-seven (21.6%) women had HSV-2 
Women screened (750)
A
B
Women with HSV-2/GH (97)
HSV-2 antibody positive only
(60, 61.9%)
Genital herpes history
(37, 38.1%)
HSV-2a (60, 100%)
Suppression (33, 55%) Suppression (21, 77.8%) Suppression (3, 30%)
HSV-2b (27, 73%) HSV-1 (10, 27%)
No exposure data
(144, 19.2%)
Excluded (157, 25.9%)
– Active genital lesions (2)
– Non-vertex fetus (55)
– Scheduled C-section (100)
Women with exposure data (606, 80.8%)
Women analyzes (449, 74.1%)
Women with HSV-2/GH
(97, 21.6%)
Women without HSV-2/
GH (352, 78.4%)
Figure 1. (A) shows a flow diagram of study participant selection. Charts were reviewed from 750 women with consecutive deliveries at University of Washington Medical 
Center in 2006, 606 of which had exposure data. After excluding women with active genital lesions, nonvertex fetal presentation, and scheduled cesarean births, 449 women 
were included in the analysis. Of these, 97 (21.6%) had herpes simplex virus-2 antibody positive or with a history of genital herpes (HSV-2/GH). (B) shows the distribution of 
HSV-2 antibody positivity and clinical history of genital herpes in the 97 women with HSV-2/GH. Women with a clinical history are further divided into those who were HSV-2 
antibody positive and those positive for antibodies to HSV-1 only. The distribution of the 57 women (58.8%) on suppressive anti-HSV therapy is also shown. aHSV-1 antibodies 
detected in 39 (65%); bHSV-1 antibodies detected in 14 (51.9%). C-section, cesarean section. 
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antibody or a clinical history of genital herpes. Of 60 HSV-2-
seropositive women without a clinical history of genital herpes, 
33 (55%) received suppressive antiviral therapy at the end of 
pregnancy based on provider preference. Of 37 women with 
a clinical history of genital herpes, 24 (65%) received suppres-
sive antiviral therapy. Overall, among women with HSV-2 or 
GH, 40 (41%) were not receiving suppressive antiviral therapy 
(Figure 1B). African American women were as likely as white 
women to receive suppressive therapy (59.2% vs 60%). The 352 
women who were neither HSV-2 seropositive nor with a clinical 
history of GH were used as the comparison group.
Intrapartum procedures were performed in 16 (40.0%) of 
40 women with HSV-2/GH who were not receiving antiviral 
therapy (Figure 2), 35 (61.4%) of 57 women with HSV-2/GH 
using antiviral suppression, and 203 (57.7%) of 352 women 
without HSV-2/GH (global P  =  .08) (Figure  2). Comparable 
proportions of women in each group underwent unplanned 
cesarean births: 12 of 40 women (30.0%) with unsuppressed 
HSV-2/GH, 16 of 57 women (28.1%) with suppressed HSV-2/
GH, and 88 of 352 (25.0%) without HSV-2/GH (global P = .73).
In univariate regression analysis, women with HSV-2/GH 
who were not on suppressive antiviral therapy were less likely to 
undergo intrapartum procedures than women without HSV-2/
GH (OR, 0.49; 95% CI, 0.25–0.95; P = .036). We did not detect a 
difference in the rate of intrapartum procedures for women with 
HSV-2/GH on suppressive therapy compared with women with-
out HSV-2/GH (OR, 1.17; 95% CI, 0.66–2.07; P = .60). Women 
ages 39 and older were much less likely to undergo intrapartum 
procedures than women 20 years and younger (OR, 0.11; 95% 
CI, 0.04–0.35; P ≤ .001). Intrapartum procedures were used less 
frequently in multiparous women than in primiparous women 
(OR, 0.62; 95% CI, 0.42–0.90; P  =  .01) and in women with 
multiple gestation pregnancies compared with women with 
singleton pregnancies (OR, 0.23; 95% CI, 0.09–0.60; P = .003). 
Prematurity was associated with a decreased likelihood of intra-
partum procedures (OR, 0.46; 95% CI, 0.29–0.73; P = .001), but 
failure to progress in labor was associated with an increased like-
lihood (OR, 2.22; 95% CI, 1.21–4.08; P = .01). Compared with 
white woman, African American women were as likely (OR, 
1.02; 95% CI, 0.59–1.77; P = .95) and Asian women were more 
Table  1. Demographic and Clinical Factors of Women Included in 
Analysisa 
Factor
HSV-2/GH
Total PcYes, n (%)b No, n (%)b
All subjects 97 (21.6) 352 (78.4) 449
 Antiviral suppression  57 (58.8)
 No antiviral suppression  40 (41.2)
Mean age (n = 448) 31.1 30.0 30.2 .126d
Race (n = 440) <.001
 African American  27 (28.1)  34 (9.9)  61 (13.9)
 Asian  10 (10.4)  60 (17.4)  70 (15.9)
 White  55 (57.3)  237 (68.9)  292 (66.4)
 Biracial/other  4 (4.2)  13 (3.8)  17 (3.9)
Hispanic ethnicity (n = 434)  7 (7.5)  37 (10.9)  44 (10.1) .347
Non-Hispanic  86 (92.5)  304 (89.2)  390 (89.9)
Married (n = 446)  53 (55.2)  272 (77.7)  325 (72.9) <.0001
Not married  43 (44.8)  78 (22.3)  121 (27.1)
Multiparous  55 (56.7)  163 (46.3)  218 (48.6) .070
Primiparous  41 (43.3)  189 (53.7)  231 (51.5)
Premature  25 (25.8)  65 (18.5)  90 (20.0) .111
Not premature  72 (74.2)  287 (81.5)  359 (80.0)
Multiple gestation (n = 442)  7 (7.4)  17 (4.9)  24 (5.4) .347
Singleton  88 (92.6)  330 (95.1)  418 (94.6)
High-risk conditione  58 (59.8)  181 (51.4)  239 (53.2) .143
No high-risk condition  39 (40.2)  171 (48.6)  210 (46.8)
HSV-1 antibody positive 
(n = 441)
 62 (66.7)  223 (64.1)  285 (64.6) .643
HSV-1 antibody negative  31 (33.3)  125 (35.9)  156 (35.4)
Any intrapartum procedure  51 (52.6)  203 (57.7)  254 (56.6) .370
No intrapartum procedure  46 (47.4)  149 (42.3)  195 (43.4)
Intrapartum Procedure by Type
 Fetal scalp electrodes  10 (10.3)  51 (14.5)  61 (13.6)
 AROM  35 (36.1)  144 (40.9)  179 (39.9)
 IUPC  27 (27.8)  89 (25.3)  116 (25.8)
 Vacuum extraction  4 (4.1)  11 (3.1)  15 (3.3)
 Forceps extraction  4 (4.1)  6 (1.7)  10 (2.2)
Cesarean section  28 (28.9)  88 (25.0)  116 (25.8) .441
Vaginal delivery  69 (71.1)  264 (75.0)  333 (74.2)
Abbreviations: AROM, artificial rupture of membranes; HSV, herpes simplex virus; HSV-2/
GH, HSV-2 antibody positive or clinical history of genital herpes; IUPC, intrauterine pres-
sure catheter.
aN = 449 except as noted.
bColumn percentage as a subset of the total for each covariate presented; percentage 
may not sum to 100% due to rounding.
cCalculated with χ2 test except as noted.
dTwo-sided t test.
eAsthma, diabetes, hypertension, pre-eclampsia, renal or cardiac disease, intrauterine 
growth restriction, oligohydramnios, congenital anomaly.
70%
No HSV-2/GH
HSV-2/GH, on
suppressive therapy
HSV-2/GH, not on
suppressive therapy
P = .08
P = .73
60%
50%
40%
30%
20%
10%
0%
Intrapartum
procedure
Intrapartum
C-section
Figure  2. Proportions of women undergoing intrapartum procedures and ce-
sarean delivery, by risk group, are shown. Risk groups include asymptomatic women 
with and without herpes simplex virus (HSV)-2 antibody positivity or a clinical his-
tory of genital herpes (HSV-2/GH). Women with HSV-2/GH are further stratified by 
whether or not they were receiving suppressive antiviral therapy at delivery. Global 
P values for differences between groups are shown. C-section, cesarean section.
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likely (OR, 1.88; 95% CI, 1.09–3.26; P = .02) to undergo intra-
partum procedures. Seventeen women categorized as biracial or 
of other racial backgrounds were examined as a single category; 
16 of these women underwent an intrapartum procedure (OR, 
14.74; 95% CI, 1.93–112.58; P = .01). Covariates examined for 
associations with intrapartum procedures that were not signifi-
cant on univariate analysis included Hispanic ethnicity, marital 
status, high-risk pregnancy, obesity, infection with another STD 
during pregnancy, group B streptococcus culture-positive, fetal 
distress, placental abruption, and induction of labor.
On multivariate analysis, after adjusting for age, race, prema-
turity, and failure to progress in labor, the association between 
HSV-2/GH status and intrapartum procedures in women was 
attenuated and no longer statistically significant. Women with 
unsuppressed HSV-2/GH had somewhat lower risk of intra-
partum procedures compared with women without HSV-2/
GH (OR, 0.69; 95% CI, 0.34–1.41; P = .31). In contrast, women 
with suppressed HSV-2/GH had somewhat higher risk of 
intrapartum procedures compared with women without HSV-2/
GH (OR, 1.41; 95% CI, 0.77–2.72; P = .26) (Table 2). To exam-
ine the effect of race on the model, the analysis was repeated 
excluding the “biracial/other” category and again excluding the 
entire race covariate, but these had only a minor impact on the 
adjusted ORs.
Potential predictors of cesarean births were also explored. 
On univariate analysis, we did not detect any increase in likeli-
hood of cesarean delivery for women with unsuppressed (OR, 
1.29; 95% CI, 0.63–2.64; P  =  .49) or suppressed HSV-2/GH 
(OR, 1.17; 95% CI, 0.63–2.19; P = .62) relative to women with-
out HSV-2/GH. Multiparity was associated with a decreased 
likelihood of undergoing cesarean births (OR, 0.53; 95% CI, 
0.35–0.82; P  =  .004), and high-risk pregnancy was associated 
with an increased likelihood (OR, 1.89; 95% CI, 1.22–2.92; 
P  =  .004). Multiple gestation (OR, 4.51; 95% CI, 1.94–10.47; 
P < .001), prematurity (OR, 1.81; 95% CI, 1.10–2.97; P = .02), 
and chorioamnionitis (OR, 3.38; 95% CI, 1.58–7.25; P = .002) 
Table 2. Predictors of Invasive Obstetric Procedurea Use at Delivery
N = 449b
Invasive Procedure
OR (95% CI) P aOR (95% CI) PYes, n (%)c No, n (%)c
HSV-2/GH Status
 Uninfected 149 (76.4) 203 (79.9) Ref .08d Ref .25d
 Antiviral suppression 35 (13.8) 22 (11.3) 1.17 (0.66–2.07) .60 1.45 (0.77–2.72) .26
 No antiviral suppression 16 (6.3) 24 (12.3) 0.49 (0.25–0.95) .04 0.69 (0.34–1.41) .31
Age (Years)
 ≤20 24 (9.5) 8 (4.1) Ref <.001d Ref .01d
 21 to 38 222 (87.4) 163 (83.6) 0.45 (0.20–1.04) .06 0.51 (0.21–1.25) .14
 ≥39 8 (3.2) 24 (12.3) 0.11 (0.04–0.35) <.001 0.15 (0.05–0.50) .002
Race (n = 440)
 White 152 (61.5) 140 (72.5) Ref .01d Ref .03d
 Asian 47 (19) 23 (11.9) 1.88 (1.09–3.26) .02 1.84 (1.04–3.25) .04
 African American 32 (13) 29 (15) 1.02 (0.59–1.77) .95 1.17 (0.64–2.14) .62
 Biracial/Other 16 (6.5) 1 (0.5) 14.74 (1.93–112.6) .01 11.35 (1.46–88.5) .02
Hispanic (n = 434) 25 (10.2) 19 (10.1) 1.02 (0.54–1.91) .96
Married (n = 446) 186 (73.8) 139 (71.7) 1.11 (0.73–1.70) .61
Multiparous 110 (43.3) 108 (55.4) 0.62 (0.422–0.90) .01 0.65 (0.42–0.99) .05
High-riske 134 (52.8) 105 (53.9) 0.96 (0.66–1.39) .82
Obesity 30 (11.8) 24 (12.3) 0.95 (0.54–1.69) .87
Multiple gest. (n = 442) 6 (2.4) 18 (9.5) 0.23 (0.09–0.60) .003
Other STDf 21 (8.3) 23 (11.8) 0.67 (0.36–1.26) .22
GBS positive (n = 421) 69 (28.8) 57 (31.5) 0.88 (0.58–1.34) .54
Premature 37 (14.6) 53 (27.2) 0.46 (0.29–0.73) .001 0.43 (0.26–0.72) .001
Failure to progress 42 (16.5) 16 (8.2) 2.22 (1.21–4.08) .01 1.98 (1.03–3.82) .04
Fetal distress 22 (8.7) 25 (12.8) 0.65 (0.35–1.18) .16
Placental abruption 2 (0.8) 5 (2.6) 0.30 (0.06–1.57) .16
Induction of labor 58 (22.8) 42 (21.5) 1.08 (0.69–1.69) .74
Abbreviations: aOR, odds ratio adjusted for age, race, multiparity, prematurity, failure to progress in labor; CI, confidence interval; GBS, group B streptococcus culture; gest., gestation; 
HSV-2/GH, herpes simplex virus type 2 seropositive or clinical history of genital herpes; OR, odds ratio; Ref, reference category; STD, sexually transmitted disease.
aFetal scalp electrode, artificial rupture of membranes, intrauterine pressure catheter, vacuum extraction or forceps extraction.
bExcept where noted otherwise.
cPercentages may not sum to 100% because of rounding.
dGlobal P value for all categories.
eAsthma, diabetes, hypertension, pre-eclampsia, renal or cardiac disease, intrauterine growth restriction, oligohydramnios, congenital anomaly.
fSyphilis, gonorrhea, chlamydia, trichomoniasis, or human papillomavirus diagnosed during pregnancy.
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were all associated with an increased likelihood of cesarean 
delivery. Covariates not found to have a significant association 
with cesarean birth on univariate analysis included age, race, 
Hispanic ethnicity, marital status, obesity, other STDs during 
pregnancy, positive group B streptococcus culture, preterm rup-
ture of membranes, placental abruption, and induction of labor.
After adjusting for parity, high-risk pregnancy, and multiple 
gestation pregnancy in a multivariate model, we did not detect 
a significant increase in the likelihood of cesarean delivery in 
women with HSV-2/GH. This was true regardless of whether 
they were receiving (OR, 1.21; 95% CI, 0.63–2.33; P =  .57) or 
not receiving suppressive antiviral therapy (OR, 1.13; 95% CI, 
0.51–2.50; P = .76) (Table 3).
DISCUSSION
To our knowledge, this is the first study to evaluate the effect 
of prenatal HSV antibody screening programs on management 
of labor. We found that the rate of intrapartum invasive pro-
cedures was lower among asymptomatic pregnant women with 
antibodies to HSV-2 or a clinical history of genital herpes who 
were not receiving suppressive antiviral therapy compared with 
women without HSV-2 antibodies or a history of genital herpes, 
although the relationship was not significant after adjustment 
for potential confounders. Furthermore, women with antibod-
ies to HSV-2 or a clinical history of genital herpes who received 
suppressive therapy were at similar risk for intrapartum pro-
cedures compared with women without HSV-2 antibodies or a 
clinical history of genital herpes.
Shedding of HSV in the maternal genital tract during birth 
poses substantial risk of neonatal herpes, but prolonged amni-
otic membrane disruption, vacuum-assisted delivery, and fetal 
scalp monitors have also been shown to increase the risk of 
neonatal HSV [1, 10, 11]. Collectively, the relevant literature 
strongly suggests that any intrapartum instrumentation that can 
breach the infant skin should be avoided in the setting of pos-
sible maternal mucosal HSV shedding. Current practice guide-
lines suggest using suppressive antiviral therapy for women with 
a history of recurrent genital HSV lesions in pregnancy, which 
reduces recurrence of genital herpes, viral shedding, and rate of 
cesarean delivery use, but evidence that this strategy prevents 
neonatal herpes is lacking [12, 16–21]. Furthermore, in the last 
2 decades, a period in which this approach has been increasingly 
popular, there has been no change in the incidence of neonatal 
herpes in the United States [1–6]. This is consistent with the 
observation in nonpregnant women with genital HSV infection 
that antiviral therapy reduces but does not eliminate subclini-
cal HSV shedding from genital mucosa [22, 23]. A recent series 
reported 8 cases of neonatal herpes in infants whose mothers 
received antiviral suppression at the end of pregnancy [24]. 
Thus, management of women with genital herpes with antiviral 
therapy does not eliminate the risk of neonatal herpes. The find-
ings from our study suggest that, at our institution, providers 
modify their use of intrapartum procedures that increase risk of 
neonatal herpes in asymptomatic HSV-2 infected women with 
known, unsuppressed genital HSV infection, but that women 
who are receiving suppressive antiviral therapy are considered 
to be at low risk and are managed similarly to women without 
genital HSV infection. These findings indicate that improved 
provider education about the risks of intrapartum procedures 
and breakthrough neonatal herpes despite suppressive therapy 
is warranted.
We also investigated the impact of prenatal HSV testing on 
the use of cesarean births. Cesarean delivery is recommended 
for women who have active genital herpes lesions at term [12]. 
Table 3. Predictors of Cesarean Section Use at Delivery
N = 449a
Unplanned Cesarean Birth
OR (95% CI)b P aOR (95% CI)b PYes, n (%)c No, n (%)c
HSV-2/GH status
 Uninfected 88 (75.9) 264 (79.3) Ref .73d Ref .83d
 Antiviral suppression 16 (13.8) 41 (12.3) 1.17 (0.63–2.19) .62 1.21(0.63–2.33) .57
 No antiviral suppression 12 (10.3) 28 (8.4) 1.29 (0.63–2.64) .49 1.13 (0.51–2.50) .76
Multiparous 43 (37.1) 175 (52.6) 0.53 (0.35–0.82) .004 0.51 (0.32–0.80) .003
High-riske 75 (64.7) 164 (49.3) 1.89 (1.22–2.92) .004 1.95 (1.23–3.08) .003
Multiple gest. (n = 442) 14 (12.4) 10 (3.0) 4.51 (1.94–10.47) <.001 4.56 (1.92–10.81) .001
Premature 32 (27.6) 58 (17.4) 1.81 (1.10–2.97) .02
Chorioamnionitis 15 (12.9) 14 (4.2) 3.38 (1.58–7.25) .002
Abbreviations: aOR, odds ratio adjusted for multiparity, high-risk pregnancy, multiple gestation; CI, confidence interval; gest., gestation; HSV-2/GH, herpes simplex virus type 2 seropositive 
or clinical history of genital herpes; OR, odds ratio; Ref, reference category.
aExcept where otherwise noted.
bAge, race, Hispanic ethnicity, marital status, obesity, other sexually transmitted disease during pregnancy (syphilis, gonorrhea, chlamydia, trichomoniasis, or human papillomavirus), group 
B streptococcus culture positive, preterm rupture of membranes, placental abruption, and induction of labor were not associated with increased risk of intrapartum cesarean birth.
cPercentages may not sum to 100% because of rounding.
dGlobal P value for all categories.
eAsthma, diabetes, hypertension, pre-eclampsia, renal or cardiac disease, intrauterine growth restriction, oligohydramnios, congenital anomaly.
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However, one potential consequence of prenatal HSV testing 
is increased use of medically unwarranted cesarean delivery 
in women with asymptomatic genital HSV infection [13, 14]. 
In this study, we did not observe such an increase in cesarean 
births in our cohort of women who had undergone prenatal 
HSV testing, showing that this concern is unfounded. Pregnant 
women with HSV-2 antibodies or a clinical history of genital 
herpes, but without active lesions, underwent cesarean births 
with similar frequency as women without such history, and 
antiviral suppressive therapy did not affect this outcome.
This study offers evidence that routine prenatal HSV testing 
does not result in harm by increasing cesarean delivery and that 
such testing may benefit women who are identified as HSV-2 
antibody positive. Specifically, our findings suggest that pro-
viders may be more wary of use of intrapartum procedures 
that could increase the risk of HSV transmission to neonates 
delivered by asymptomatic women with known genital HSV 
infection. Although most obstetricians believe neonatal herpes 
merits systematic prevention strategies, few report performing 
regular prenatal HSV antibody testing outside of academic set-
tings [25]. In addition to cesarean delivery use, costs and psy-
chosocial burdens of prenatal HSV testing have been put forth 
as concerns [13, 14, 26]. Cost-effectiveness models of neonatal 
herpes prevention strategies that include prenatal HSV-2 anti-
body testing are conflicting, although the most recent models 
are more favorable [26–30]. With regard to the psychosocial 
burden, in a recent systematic review of studies exploring the 
impact of HSV-2 antibody testing in asymptomatic persons, 
most participants testing positive did not suffer sustained emo-
tional harm [31]. In pregnancy, the motivation to be tested may 
be higher because there is a desire to protect the fetus. Of note, 
studies assessing the acceptability of such programs suggest that 
pregnant women are amenable to prenatal HSV testing [32–34]. 
More targeted prenatal HSV screening would likely miss a sub-
stantial proportion of cases [2]. However, routine prenatal 
screening alone is unlikely to impact the incidence of neonatal 
herpes, because the greatest risk occurs in women who acquire 
genital herpes late in pregnancy and lack detectable HSV anti-
bodies at delivery [1]. Further strategies need to be developed to 
identify women who are infected near the time of delivery and 
are asymptomatic.
Our study has several limitations. Observational studies are 
subject to the effects of unmeasured confounding, and a ran-
domized trial of prenatal HSV testing would be necessary to 
address this problem. The size of the study population also lim-
ited our approach to the analysis in several ways. We could not 
assess neonatal herpes as an outcome. In addition, to increase 
statistical power, we combined all women with evidence of 
genital HSV infection regardless of prior symptom history, 
as long as they were asymptomatic at delivery. An impor-
tant limitation in our analysis is the lack of unified manage-
ment of HSV-2, likely due to physicians practice and women’s 
preference. It is possible that providers treated women with a 
clinical history of genital herpes differently from HSV-2 anti-
body positive women without any such history. Thus, a poten-
tial bias for antiviral treatment in patients with clinical and 
serological diagnosis of genital herpes could have extended 
to the use of obstetric procedures and cesarean delivery use, 
although we are not clear whether these would be positively or 
negatively associated. Because our data come from a teaching 
hospital, the delivering physician is not always the same phy-
sician that provides prenatal care. Therefore, examining asso-
ciations between antiviral therapy and intrapartum procedures 
may not be helpful.
We also lacked the power to assess the effect of the exposure 
on individual intrapartum procedures. Combining these out-
comes may have masked differing associations between the ex-
posure and individual procedure use. There are also inherent 
limitations to using chart data to assess provider behavior, and 
provider decision making was not measured directly, and some 
interventions may not be recorded in the chart. Finally, this 
study was conducted at an academic medical center with strong 
institutional knowledge of neonatal herpes disease and risk 
factors. The impact of prenatal HSV testing programs, in the 
absence of clear guidelines for management of asymptomatic 
women with genital HSV infection, could differ substantially 
by setting. In our population, suppressive antiviral therapy was 
administered to some HSV-2 antibody positive women without 
a clinical history of genital herpes, which is not currently rec-
ommended [12].
CONCLUSIONS
Improved interventions are needed to reduce neonatal herpes. 
In our study, identification of women with HSV-2 infection 
with a routine prenatal antibody testing program appeared to 
reduce the use of procedures known to increase neonatal herpes 
risk in women not on antiviral suppression without an increase 
in cesarean sections.
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